anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
According to the American Heart Association（AHA）modified Adult Treatment Panel III（ATP-III） and the criteria of Health Promotion Administration, Taiwan. Five indices are used to define metabolic syndrome（MetS): including waist circumference （WC), high blood pressure（H/P）, fasting plasma glucose（FPG）, triglyceride（TG）, and high-density lipoprotein-cholesterol（HDL-C）. The recent researches showed us, there was no research applying the five criteria into their decision model. This study proposal will be the first study which evaluated the importance of the criteria related to apply these indices and decision model into the clinic for risk factors assessment.

This study was divided into 2 stages: (1) to analyze the big database of health examination to find out the major decision-making analysis module of MetS, including the level of importance and decision-making weight of 5 indicators, which can be provided as reference for suggestions on clinical medical treatments or health education focuses of health management of sub-health population; (2) to analyze other demographic variables of the database (educational background, residence, occupation, etc.) and the variables affecting health patterns (including smoking, drinking, long-term sitting work pattern) to find out the important variables affecting high risk group for MetS among populations of all ages, in order to investigate the improvement strategies for early prevention or intervention of important variables. As aging society is coming, it is estimated that the elderly people over the age of 65 in Taiwan will reach 20% by 2025. According to the estimation of Executive Yuan, the growth rate of healthcare service industry will reach at least 17%, and the annual output value will reach USD 18 billion. Therefore, this study intends to develop strategies for preventing chronic illness in the middle-aged and elderly people and find out the characteristic variables of high risk group according to different age groups to further reduce the incidence of MetS or CVD.
PURPOSE: A formulation for topical application to human skin containing ginsenoside Rh2 and/or ginsenoside Rg3 as an effective ingredient is provided. The dermatological formulation includes drugs, quasi-drugs and cosmetics and has excellent normalizing effect on cutaneous immune and cell-activating effect. CONSTITUTION: The formulation for topical application to human skin contains 0.0001 to 10% by weight of ginsenoside Rh2 and/or ginsenoside Rg3 in the shape of solids. The formulation is selected from creams, sprays, gelling agents, emulsions or lotions. The ginsenoside Rh2 and/or ginsenoside Rg3 are obtained by extracting Panax ginseng C. A. Meyer, Panax japonicus C. A. Meyer, Panax notoginseng (Burk. ) F. H. Chen or Panax quinquefolium (American or white ginseng) after enzymatic treatment.
Dimethyl fumarate delayed-release capsules, USP contain dimethyl fumarate which is also known by its chemical name, Dimethyl (2E)-but-2-enedioate, (C6H8O4). It has the following structure:

Dimethyl fumarate, USP is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13. 

Dimethyl fumarate delayed-release capsules are provided as hard-shell gelatin delayed-release capsules for oral administration, containing 120 mg or 240 mg of dimethyl fumarate consisting of the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, methacrylic acid and ethyl acrylate copolymer, methacrylic acid and methyl methacrylate copolymer, microcrystalline cellulose, polysorbate 80, sodium lauryl sulfate, talc and triethyl citrate. The capsule shell contains black iron oxide, FD&C Blue No. 2 Aluminum Lake, gelatin, sodium lauryl sulfate, titanium dioxide and yellow iron oxide.

In addition, the black imprinting ink contains ammonium hydroxide, black iron oxide, propylene glycol and shellac glaze.
Androgen suppression (AS) (Luteinizing hormone releasing hormone agonist and bicalutamide \[Casodex\] or flutamide \[Eulexin\]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide \[Casodex\] or flutamide \[Eulexin\]). AS will continue for a total of 24 months from initiation of all treatment. Oral anti-androgen will be discontinued at the end of radiation therapy (RT).
Embodiments relate to a magnetic resonance imaging apparatus. The magnetic resonance imaging apparatus which can position cross-sectional images easily by users is provided. The magnetic resonance imaging apparatus according to embodiments includes a memory part, a detection pat and a display and control part. The memory part meomorizes layout information of a plurality of cross-sectional images on a positioning picture. The detection part detects cross-sectional positions of a plurality of the cross-sectional images according to collected data. The display and control part displays according to at leat one layout information in the plurality of layout information on the positioning picture, based on all or a part of a plurality of cross-sectional images generated at a plurality of cross-sectional positions.
A wound dressing 10 comprising a first skin contacting layer 16 formed from a flexible and liquid permeable or semi-permeable material, and an opposing second layer 18 formed from a flexible and liquid-absorbent material. In use both layers 16, 18 are at least partially sealed or joined together with a layer of granulated sugar 20 provided therebetween. In one arrangement the dressing 10 is provided as a pouch with only the peripheral edges 14 of the layers 16, 18 sealed together to define a cavity 22 therebetween, with the granulated sugar 20 provided within the cavity 22. In another arrangement both layers (16, 18; Fig 3) are placed in opposition and secured together across their entire extent by means of an adhesive. In this arrangement the sugar may be dispersed through the adhesive, which may be provided as spun sugar. Alternatively the sugar may be impregnated within apertures formed in the first layer (16, Fig 3), which is provided as a mesh in this arrangement.
Adults with severe mental illness (SMI) are three times more likely to smoke than non-SMI adults, consuming 35-44% of all cigarettes in the U.S.; and, the highest rates of tobacco-related illnesses and death are among smokers with schizophrenia. Unfortunately, not only are patients with schizophrenia less likely to receive smoking treatments, but cessation medications are only modestly effective in helping this subset of smokers quit. Therefore, it is vital to discover new treatment adjuncts that specifically aid this high-risk subset of smokers to achieve successful abstinence. Toward that end, the investigators propose a novel non-pharmacologic technique that directly targets both cognitive impairment, an avenue considerable past research suggests may be particularly effective to exploit in smokers with schizophrenia, and reactivity to prepotent stimuli, shown to be enhanced in smokers with schizophrenia. Combining a subset of cognitive enhancement therapy known as Cognitive Remediation (CR), with another safe and effective technique, Transcranial Direct Current Stimulation (tDCS), the investigators propose a new cognitive training method aimed at enabling smokers with schizophrenia to gain greater control over smoking and stimuli-induced reactivity (e.g., craving). Recent studies have found significant tDCS-induced cognitive enhancement, as well as reduction in both cue-induced craving and smoking behavior among healthy smokers. This combined with knowledge of the cognitive deficits that exist among individuals with schizophrenia, and clear evidence of a relationship between cognitive function and smoking treatment success, provides the rationale for testing novel CR + tDCS to target underlying mechanisms of smoking among individuals with schizophrenia. Specifically, the proposed study will examine the extent to which targeted cognitive enhancement with CR + tDCS, leads to changes in cognitive control, cue-provoked craving, reaction time and ERP measures of attentional bias; as well as the impact of these changes on smoking behavior and intention and confidence to quit among 80 smokers with schizophrenia. The goal of this study is to inform the development of new non-medication, noninvasive, therapeutic techniques to specifically target smoking among patients with schizophrenia. The long term goal is to establish an effective treatment adjunct to help smokers with schizophrenia successfully achieve abstinence.
BACKGROUND: Elderly patients are at increased risk of perioperative morbidity and mortality after conventional on-pump coronary artery bypass grafting (ONCABG). This study was to determine whether such high-risk population would benefit from off-pump coronary artery bypass grafting (OPCABG).
METHODS: A retrospective analysis was performed on patients aged 65 years or older who underwent isolated coronary artery bypass grafting for the first time in Wuhan Union Hospital from January 2015 to January 2021. We used propensity score matching to adjust for differences in baseline characteristics between the ONCABG and OPCABG groups. Morbidity and mortality within 30 days after surgery were compared between the two groups. All operations were performed by experienced cardiac surgeons.
RESULTS: A total of 511 patients (ONCABG 202, OPCABG 309) were included. After 1:1 matching, the baseline characteristics of the two groups were comparable (ONCABG 173, OPCABG 173). The OPCABG group had higher rate of incomplete revascularization (13.9% vs. 6.9%; P = .035) than the ONCABG group. However, OPCABG reduced the risk of postoperative renal insufficiency (15.0% vs. 30.1%; P = .001) and reoperation for bleeding (0.0% vs. 3.5%; P = .030). There were no significant differences in early postoperative mortality, myocardial infarction, stroke, and other outcomes between the two groups.
CONCLUSIONS: OPCABG is an alternative revascularization method for elderly patients. It reduces the risk of early postoperative renal insufficiency and reoperation for bleeding.
An osmotic system for delivering an agent is disclosed. The system comprises a wall surrounding a compartment and has a passageway through the wall for delivering agent from the compartment. The wall is formed of a material permeable to the passage of an external fluid and impermeable to the passage of agent. The compartment contains an agent that is soluble in the fluid and exhibits an osmotic pressure gradient across the wall against the fluid, or the compartment contains an agent that has limited solubility in the fluid and exhibits a limited osmotic pressure gradient across the wall against the fluid. The compartment also contains a suspending agent and a delivery member for increasing the amount of agent delivered from the system. The delivery member comprises a semipermeable film surrounding an osmotically effective compound and it is able to increase in volume over time. In operation, agent is delivered from the system through the passageway at a controlled rate by fluid being imbibed through the wall into the compartment to produce a solution or suspension containing agent, and for urging the member to increase in volume and fill the compartment, whereby agent is released at a rate controlled by the permeability of the wall, the osmotic pressure gradient across the wall, and the increase in volume of the member over a prolonged period of time.
A new concept of computer system is provided to relax stresses such as fatigue, VDT syndrome, occupational diseases or psychogenic possibly gained from long hours of computer usage. This new computer system is able to divert the negative effects of conventional computer to affirmative effects by introducing the aroma therapy. The new computer system provides not only the data programs of establishing, playing execution and controlling, but also the stress relief program comprising acoustic therapy, color therapy, fragrance therapy and tactual therapy and a stress perception program. The stress relief program is operated by an emission device through a converter. The equipment of the stress relief is installed on a peripheral device of computer such as a speaker, keyboard or monitor. The new concept of computer system for stress relaxation originates a combination of the computer system and the natural therapies applied the human senses like sight, hearing, feeling and smelling senses. With this new computer system, the computer user has a merit of stress relief during the computer operating.
Fluoroquinolones, including ciprofloxacin extended-release tablets, are associated with an increased risk of tendinitis and tendon rupture in all ages. This adverse reaction most frequently involves the Achilles tendon, and rupture of the Achilles tendon may require surgical repair. Tendinitis and tendon rupture in the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendon sites have also been reported. The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Factors, in addition to age and corticosteroid use, that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis. Tendinitis and tendon rupture have also occurred in patients taking fluoroquinolones who do not have the above risk factors. Tendon rupture can occur during or after completion of therapy; cases occurring up to several months after completion of therapy have been reported. Ciprofloxacin extended-release tablets should be discontinued if the patient experiences pain, swelling, inflammation or rupture of a tendon. Patients should be advised to rest at the first sign of tendinitis or tendon rupture, and to contact their healthcare provider regarding changing to a non-quinolone antimicrobial drug.

Exacerbation of Myasthenia Gravis: Fluoroquinolones, including ciprofloxacin extended-release tablets, have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis. Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolone use in persons with myasthenia gravis. Avoid ciprofloxacin extended-release tablets in patients with known history of myasthenia gravis. (See PRECAUTIONS: Information for Patientsand ADVERSEREACTIONS: Post-Marketing Adverse Event Reports).

THE SAFETY AND EFFECTIVENESS OF CIPROFLOXACIN EXTENDED-RELEASE TABLETS IN PEDIATRIC PATIENTS AND ADOLESCENTS (UNDER THE AGE OF 18 YEARS), PREGNANT WOMEN, AND NURSING WOMEN HAVE NOT BEEN ESTABLISHED. (See PRECAUTIONS: Pediatric Use,Pregnancy,and Nursing Motherssubsections.) The oral administration of ciprofloxacin caused lameness in immature dogs. Histopathological examination of the weight-bearing joints of these dogs revealed permanent lesions of the cartilage. Related quinolone-class drugs also produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species.(See ANIMALPHARMACOLOGY.)
Disopyramide phosphate is an antiarrhythmic drug available for oral administration in immediate-release capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. The base content of the phosphate salt is 77.6%. The structural formula of disopyramide phosphate is:

Disopyramide phosphate is freely soluble in water, and the free base (pKa 10.4) has an aqueous solubility of 1 mg/ml. The chloroform:water partition coefficient of the base is 3.1 at pH 7.2.

Disopyramide phosphate is a racemic mixture of d- and l- isomers. This drug is not chemically related to other antiarrhythmic drugs.

Inactive ingredients of disopyramide phosphate include corn starch, edible ink, FD&C Red No. 3, FD&C Yellow No. 6, gelatin, lactose, talc, and titanium dioxide; the 150-mg capsule also contains FD&C Blue No. 1.
Dazostinag 5.0 mg, infusion, IV, will be administered in participants with SCCHN at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. Pembrolizumab infusion, IV will be administered at 200 mg Q3W. Platinum-based chemotherapy comprising the combination of carboplatin (target area under the curve of 5 milligrams per milli Liters per minute (mg/mL/minute) \[AUC 5\]) or cisplatin (100 milligrams per square meter \[mg/m\^2\] Day 1 of each treatment cycle), and 5-fluorouracil (\[5-FU\]; 1000 mg/m\^2 per day for 4 consecutive days) Q3W for up to 6 cycles.
A composition comprising Christensenella sp., or a metabolite, fermentation broth, or a fermentation broth supernatant thereof, or any combination thereof. The 16S rRNA of Christensenella sp. has at least 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.99%, or 100% identity to the sequence as shown in SEQ ID NO: 1, wherein the Christensenella sp. is preferably Gram-negative Christensenella intestinihominis, and more preferably the strain with the deposit number GDMCC No: 61117. The composition can prevent or treat tumors or inflammatory diseases, or improve the efficacy of one or more tumor therapies. Experiments prove that in the environment of the intestinal tract of a mouse, Christensenella sp. can effectively inhibit the growth speed of various refractory tumors, improve the efficacy of other tumor therapies, can relieve immunosuppression, promote the transcription activity of IFN β, and has potential therapeutic efficacy on various diseases.
<P>PROBLEM TO BE SOLVED: To provide a synthesis of dicationic 3,5-diphenylisoxazole and its antiprotozoal activity.  <P>SOLUTION: New dicationic 3,5-diphenylisoxazoles are described. The synthetic route of the novel compound is provided. Several of these compounds displayed the in-vitro activity that is comparable to that of the furamidien against Plasmodium falciparum or the like. Further, almost of the novel compounds show less toxicity to the VERO cells than that of the furamidine.  <P>COPYRIGHT: (C)2007,JPO&INPIT
In making an optical component, one or more portions of a substrate's surface are patterned. At least a region of the substrate's surface is coated in negative photoresist, the region encompassing said portions. The negative photoresist becomes undevelopable when exposed to light. Light which forms a grating structure is projected over each of the portions. Light of substantially uniform intensity over the entirety of the region but for the portions, thereby leaving the negative photoresist outside of the portions undevelopable. The negative photoresist is developed so as to embody the grating structure in the photoresist covering the portions. The substrate's surface is patterned to impose the grating structure on the substrate's surface from the developed photoresist; the undevelopable photoresist inhibits patterning of the surface region outside of the portions. The optical component comprises the patterned substrate.
PURPOSE:To provide the titled emulsion storable stably in a container, by adding a sequestering agent to an aqueous solution of water-soluble inorganic iron salt, adding a water-soluble lactic acid salt, etc. in combination of a substance capable of developing black color by reacting with iron ion to the solution, and mixing the obtained mixture with an oil phase containing a surface active agent. CONSTITUTION:An aqueous solution of a water-soluble inorganic iron salt (e.g. ferric chloride) is added with a sequestering agent (e.g. disodium edetate, sodium metaphosphate, etc.) of the critical sequestering amount (e.g. 1.0-1.5pts. per 1.0pt. of ferric chloride) to effect the sequestering of the iron ion. A substance which develops black color by the reaction with iron ion (e.g. gallic acid, tannic acid, pyrogallol, etc.) is added to the mixture. Further, a water-soluble lactate or pyrrolidonecarboxylic acid salt is added to the mixture and the pH of the product is adjusted to 3.5-7.0. The obtained aqueous phase is mixed and emulsified with an oil phase (e.g. castor oil, squalane, etc.) containing a surface active agent to obtain the objective hair-dressing emulsion.
The present invention provides a novel medicament for preventing and treating diseases related to the activity of human chymosin. A human chymosin inhibitor containing a compound as shown in the following general formula (A) as an effective component shows selectivity for human chymosin and has an excellent enzyme activity inhibiting effect. Preferably, more than one component of this compound is selected from a group consisting of quercitrin, isoquercitrin, hyperoside, kaempferol and luteolin. A medicament containing the human chymosin inhibitor is a medicine used for preventing and treating various diseases related to the activity of human chymosin by means of a human chymosin activity inhibiting effect. (In the general formula (A), R1 to R5 respectively and independently represent hydroxyl or methoxyl, and X1 represents hydroxyl or -OG group. In addition, G represents a carbohydrate chain).
Ursodiol is a bile acid available as 300 mg capsules suitable for oral administration.

Ursodiol, USP (ursodeoxycholic acid), is a naturally occurring bile acid found in small quantities in normal human bile and in the biles of certain other mammals. It is a bitter-tasting, white powder freely soluble in ethanol, methanol, and glacial acetic acid; sparingly soluble in chloroform; slightly soluble in ether; and insoluble in water. The chemical name for ursodiol is 3α, 7β-Dihydroxy-5β-cholan-24-oic acid (C24H40O4). Ursodiol, USP has a molecular weight of 392.57. Its structure is shown below:

Inactive Ingredients: Corn starch, magnesium stearate, silicon dioxide and the capsule shell contain the following ingredients, gelatin, titanium dioxide, D&C Red # 28, FD&C Blue # 1 and FD&C Red # 40.

The imprinting ink contains the following: black iron oxide, D&C Yellow # 10 Aluminum Lake, FD&C Blue # 1 Aluminum Lake, FD&C Blue # 2 Aluminum Lake, FD&C Red # 40 Aluminum Lake, propylene glycol and shellac glaze.